Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.93M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Revenue growth | — | 1060.0% | 114.0% | -35.7% | 67.8% | -40.1% | -16.7% |
| Operating income | -$42.2M | -$46.3M | -$101M | -$161M | -$166M | -$262M | -$349M |
| Operating margin | -1438.5% | -136.1% | -138.0% | -344.4% | -210.6% | -555.8% | -891.1% |
| Net income | -$41.2M | -$45.6M | -$100M | -$155M | -$147M | -$224M | -$311M |
| Net margin | -1405.8% | -134.0% | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% |
| EPS (diluted) | -$24.28 | -$3.15 | -$2.09 | -$2.87 | -$2.52 | -$2.98 | -$3.69 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $17.9M | $88.1M | -$129M | -$153M | -$103M | -$195M | -$233M |
| Capital expenditures | $532K | $9.10M | $1.60M | $2.84M | $34.5M | $12.8M | $1.45M |
| Free cash flow | $17.4M | $79.0M | -$131M | -$156M | -$137M | -$207M | -$234M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $76.0M | $31.0M | $48.0M | $68.4M | $110M | $120M | $357M |
| Total assets | $117M | $487M | $606M | $603M | $576M | $978M | $1.74B |
| Total liabilities | $82.0M | $203M | $146M | $113M | $181M | $142M | $163M |
| Shareholders' equity | -$74.4M | $284M | $460M | $490M | $395M | $836M | $1.58B |
| Retained earnings | -$76.5M | -$129M | -$229M | -$384M | -$531M | -$755M | -$1.07B |
| Shares (wtd avg diluted) | 1.93M | 17.3M | 48.0M | 53.9M | 58.4M | 75.0M | 84.5M |
Every figure is extracted from Kymera Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.